

Neuland reports record FY26 revenue of ~\$215M, driven by commercial NCE programs

Hyderabad, India, May 12, 2026: Neuland Laboratories, a global contract development and manufacturing organization (CDMO) specializing in complex APIs, has reported **record full-year revenues exceeding ₹2000 crore (approximately \$215 million) for FY26**, marking a significant milestone in the company's growth.

This performance was driven by strong momentum in commercial-stage New Chemical Entity (NCE) programs, particularly from North American customers, reflecting increasing demand for reliable development and manufacturing partners for complex molecules.

The company also delivered a strong finish to the year, with **Q4 FY26 revenues reaching approximately \$83 million**, representing a **135% year-on-year increase**. EBITDA for the quarter rose to **₹319.4 crore (~\$33 million)**, translating to an **EBITDA margin of 40%**, while profit after tax stood at **₹212.5 crore (~\$22 million)**.

Commenting on the performance, **Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, Neuland Laboratories**, said: "We are pleased to have achieved this milestone for FY26, supported by growth in commercial and near-commercial programs. We continue to see strong business visibility in both the short and medium term, anchored by a robust pipeline of molecules progressing through development and commercialization."

The company noted that its **investments in commercial-scale API and peptide manufacturing capabilities** are beginning to contribute to growth, aligning with increasing industry demand for complex modalities. Earlier this year, Neuland announced a phased investment in a **new commercial peptide manufacturing facility**, positioning the company to support future opportunities in peptide therapeutics.

Saharsh added: "We are continuing to build for the next phase of growth, with both a new R&D centre and peptide manufacturing capacity progressing well. Our focus remains on execution discipline, customer satisfaction, and maintaining a strong regulatory track record."

Neuland currently operates **approximately 12,18,000 litres of API manufacturing capacity** across three US FDA-approved facilities. This is supported by a dedicated R&D centre located in close proximity to manufacturing sites, enabling **efficient scale-up, rapid technology transfer, and seamless transition from development to commercial supply**.

About Neuland

Neuland Laboratories Limited is an API-focused CDMO partner to pharmaceutical and biotechnology companies, providing process development and commercial manufacturing solutions for complex molecules and New Chemical Entities.

With customers in over 80 countries, Neuland operates three US FDA and EU GMP-compliant manufacturing facilities in India, with a combined reactor capacity of approximately 1218kL. The company has filed over 1,000 DMFs globally and offers more than 100 APIs across multiple therapeutic areas.

Neuland is listed on the NSE (NEULANLAB) and BSE (524558) in India.